Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

[32–34] In our study, particular interest was applied to those probe sets for which all three terms (HCV ... signatures that distinguish liver cirrhosis associated with two different etiologies ...

Background: It is currently recommended that all patients with liver cirrhosis undergo upper gastrointestinal ... We tried to identify clinical, laboratory and imaging parameters that may predict ...

This inflammation can lead to changes in the liver if it persists. Changes like fibrosis, or scarring of the tissue in the liver, may lead to cirrhosis ... (CT) scan, magnetic resonance imaging ...

Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Department of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang 421002, China ...

Canaccord rates Opthea a buy with target of $1.25 – $3 if Phase III trial is successful Opthea’s lead drug shows strong promise in eye disease trials Positive phase III results could lead to big gains ...

Akero Therapeutics has revealed preliminary topline week 96 outcomes from its Phase IIb SYMMETRY study of efruxifermin (EFX) in individuals with biopsy-confirmed compensated cirrhosis (F4), Child ...

The Akero statement underlined how well their medicine efruxifermin treats compensated cirrhosis ... liver transplants and liver cancer in the United States and Europe as well as expected to ...

a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to ...

a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin, or EFX, in patients with biopsy-confirmed compensated cirrhosis, Child-Pugh Class A, due to ...